ClinicalTrials.gg
CompletedNCT01498653Updated Jan 9, 2017Results posted

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry

A Phase 3 interventional study of GW685698/GW642444 and CCI18781 in Asthma, sponsored by GlaxoSmithKline. Completed at 24 sites in 3 countries. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
313
Allocation
Randomized
Ages
12 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing vilanterol in Asthma — none open to participants now, 2 under way, 2 of them phase 3. vilanterol · Asthma.

Enrollment
9th of 30
313 · median 69
Started
2012
with 4 others
Phase 3
14 of 30
none open now
Registered
16th of 30
by date
Lead sponsor
27 of 30
GlaxoSmithKline

Among the 30 studies testing vilanterol in Asthma, this one is the 9th largest by enrollment, is one of 5 that started in 2012, is one of 14 in phase 3, and was the 16th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 30 studies testing vilanterol in Asthma is open now. The open studies under Asthma, anywhere →

About vilanterol

vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing vilanterol in Asthma as a file.
02

Study summary

A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy

Read the detailed description

This will be a randomized, double-blind, active-comparator, parallel group, multi-center study. At Visit 1 (Screening Visit) subjects who meet all of the inclusion criteria and none of the exclusion criteria will enter a two week Run-in period. Subjects will remain on their current ICS therapy throughout the Run-in period. At the end of the Run-in period (Visit 2) subjects meeting the randomization criteria will enter a 12 week treatment period and receive one of the two following treatments: 1) FF (200mcg)/VI (25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI) 2) Fluticasone propionate 500mcg administered twice daily via DISKUS™ Inhaler In addition, all subjects will be supplied with albuterol/salbutamol inhalation aerosol to be used as required to treat asthma symptoms.

Subjects who have not met the randomization criteria at Visit 2 will be withdrawn from the study.

Subjects meeting the randomization criteria will be randomized to one of the two treatment groups and will attend the clinic for 3 on-treatment visits at Week 4 (Visit 3), Week 8 (Visit 4) and Week 12 (Visit 5). Subjects will receive treatment for 12 weeks. A Follow-up Visit or Contact (Visit 6) will take place 1 week after completing study medication. All clinic visits will take place in the morning. Subjects will participate in the study for a maximum of 15 weeks (Screening to Follow-up inclusive). A subject is regarded to have completed the study if they complete all phase of the study (Screening, treatment, Follow-up).

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. : All subjects must be able and willing to give written informed consent to take part in the study
  2. Type of Subject: Outpatients, of Asian ancestry, 12 years of age or older at Visit 1 (or ≥18 years of age or older if local regulations or the regulatory status of study medication permit enrolment of adults only) with a diagnosis of asthma as defined by the Global Initiative for Asthma [GINA, 2009] at least 12 weeks prior to Visit 1.
  3. Gender: Male or Eligible Female, defined as non- or childbearing potential using an acceptable method of consistently and correctly
  4. Severity of Disease: A best of 40%-90% of the predicted normal value at the Visit 1 Screening visit. Predicted values will be based upon NHANES III using the Asian adjustment
  5. Reversibility of Disease: Demonstrated ≥12% and ≥200mL reversibility of FEV1 within 10-40minutes following 2-4 inhalations of albuterol/salbutamol inhalation aerosol (or one nebulized treatment with albuterol/salbutamol solution) at the Screening Visit.
  6. Current Anti-Asthma Therapy: All subjects must be using an ICS, with or without LABA, for at least 12 weeks prior to Visit 1.
  7. Short-Acting Beta2-Agonists: All subjects must be able to replace their current short-acting beta2-agonists with albuterol/salbutamol inhaler at Visit 1 for use as needed for the duration of the study. Subjects must be able to withhold albuterol/salbutamol for at least 4 hours prior to study visits.

Exclusion criteria

Exclusion Criteria:

  1. History of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 10 years.
  2. Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  3. Asthma Exacerbation: Any asthma exacerbation requiring oral within 12 weeks of Visit 1 or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to Visit 1.
  4. Concurrent Respiratory Disease: A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, , or other respiratory abnormalities other than asthma.
  5. Other Concurrent Diseases/Abnormalities: A subjects must not have any , uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the patient at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study.
  6. Oropharyngeal Examination: A subject will not be eligible for the Run-in if he/she has clinical visual evidence of candidiasis at Visit 1.
  7. Allergies:

    • Drug Allergy: Any adverse reaction including immediate or delayed to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the new powder inhaler
    • Milk Protein Allergy: History of severe milk protein allergy.
  8. Concomitant Medications: Use of the protocol defined prohibited medications within the prohibited time intervals prior to Screening (Visit 1) or during the study.
  9. Tobacco Use: Current smoker or a smoking history of 10 pack years (e.g., 20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products within the past 3 months (i.e., cigarettes, cigars, smokeless or pipe tobacco).
  10. Affiliation with Investigator's Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub Investigator, study coordinator, or employee of the participating Investigator.
  11. Previous Participation: A subject may not have previously been randomized to treatment in another Phase III FF/VI combination product study
  12. Compliance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, disease, or geographical location which seems likely (in the opinion of the Investigator ) to impair compliance with any aspect of this study protocol, including visit schedule and completion of the daily diaries
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
313 participants (actual)

Study arms

  • Experimental
    FF/VI 200/25mcg once daily

    ICS/LABA

    Drug: GW685698/GW642444

  • Active comparator
    Fluticasone propionate 500mcg twice daily

    ICS

    Drug: CCI18781

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

    Peak Expiratory Flow is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 12-week Treatment Period minus the Baseline value. Analysis was performed using Analysis of Covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12 (up to Day 84)

Secondary outcomes

  1. Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12 (up to Day 84)

  2. Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

    The number of inhalations of rescue albuterol/salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 12-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline is calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12 (up to Day 84)

  3. Mean Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

    Asthma symptoms were recorded in a daily dairy by the participants every day in the morning and evening before taking any rescue or study medication and before PEF measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered as symptom free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Participants who were symptom free for 24-hour periods during the 12-week Treatment Period were assessed. Change from Baseline is calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12 (up to Day 84)

  4. Change From Baseline in Total Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12

    The AQLQ is a disease-specific, self-administered quality of life questionnaire developed to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The 32 items of the questionnaire are averaged to produce one overall quality of life score. The response format consists of a 7-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." Change from Baseline was calculated as the Week 12 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Week 12

07

Results

Posted Dec 20, 2013

Participant flow

A total of 313 participants were randomized to treatment. However, 4 participants were randomized in error and did not receive any study treatment; thus, these participants were not included in the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received \>=1 dose of trial medication.

Participant flow — Overall Study
MilestoneFluticasone Furoate/Vilanterol 200/25 µg Once DailyFluticasone Propionate 500 µg Twice Daily (BID)
Started155154
Completed136119
Not completed1935
Withdrew: Adverse event22
Withdrew: Lack of efficacy1226
Withdrew: Protocol violation04
Withdrew: Lost to follow-up10
Withdrew: Physician decision20
Withdrew: Withdrawal by subject23

Outcome measures

PrimaryMean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

Peak Expiratory Flow is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 12-week Treatment Period minus the Baseline value. Analysis was performed using Analysis of Covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12 (up to Day 84)
Reported as:
Least squares mean · Liters/minute (L/min)
Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Liters/minute (L/min)Fluticasone Furoate/Vilanterol 200/25 µg Once DailyFluticasone Propionate 500 µg Twice Daily (BID)
Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period39.1 ± 3.0110.5 ± 3.03
Statistical analysis
  • Fluticasone Furoate/Vilanterol 200/25 µg Once Daily vs Fluticasone Propionate 500 µg Twice Daily (BID) · ANCOVA · p = <0.001 · Least squares mean difference: 28.5 · 95% CI 20.1 to 36.9
SecondaryMean Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12 (up to Day 84)
Reported as:
Least squares mean · L/min
Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period
L/minFluticasone Furoate/Vilanterol 200/25 µg Once DailyFluticasone Propionate 500 µg Twice Daily (BID)
Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period46.2 ± 3.0714.0 ± 3.10
SecondaryMean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

The number of inhalations of rescue albuterol/salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 12-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline is calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12 (up to Day 84)
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
Percentage of rescue-free 24-hr periodsFluticasone Furoate/Vilanterol 200/25 µg Once DailyFluticasone Propionate 500 µg Twice Daily (BID)
Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period32.4 ± 2.9531.5 ± 2.98
SecondaryMean Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

Asthma symptoms were recorded in a daily dairy by the participants every day in the morning and evening before taking any rescue or study medication and before PEF measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered as symptom free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Participants who were symptom free for 24-hour periods during the 12-week Treatment Period were assessed. Change from Baseline is calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12 (up to Day 84)
Reported as:
Least squares mean · Percentage of symptom-free 24-hr periods
Mean Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
Percentage of symptom-free 24-hr periodsFluticasone Furoate/Vilanterol 200/25 µg Once DailyFluticasone Propionate 500 µg Twice Daily (BID)
Mean Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period25.4 ± 2.7420.6 ± 2.77
SecondaryChange From Baseline in Total Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12

The AQLQ is a disease-specific, self-administered quality of life questionnaire developed to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The 32 items of the questionnaire are averaged to produce one overall quality of life score. The response format consists of a 7-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." Change from Baseline was calculated as the Week 12 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Total Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12
Scores on a scaleFluticasone Furoate/Vilanterol 200/25 µg Once DailyFluticasone Propionate 500 µg Twice Daily (BID)
Change From Baseline in Total Asthma Quality of Life Questionnaire (AQLQ) Score at Week 120.80 ± 0.0690.69 ± 0.074

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of treatment (up to Study Day 84).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Furoate/Vilanterol 200/25 µg Once Daily—1/155 (0.6%)23/155 (14.8%)
Fluticasone Propionate 500 µg Twice Daily (BID)—2/154 (1.3%)26/154 (16.9%)
Most frequent serious events
Most frequent serious events
EventFluticasone Furoate/Vilanterol 200/25 µg Once DailyFluticasone Propionate 500 µg Twice Daily (BID)
AsthmaRespiratory, thoracic and mediastinal disorders1/1551/154
Respiratory failureRespiratory, thoracic and mediastinal disorders0/1551/154
Cardiac failureCardiac disorders0/1551/154
Drug eruptionSkin and subcutaneous tissue disorders0/1551/154
Most frequent other events
Most frequent other events
EventFluticasone Furoate/Vilanterol 200/25 µg Once DailyFluticasone Propionate 500 µg Twice Daily (BID)
Upper respiratory tract infectionInfections and infestations13/15518/154
NasopharyngitisInfections and infestations6/1556/154
Rhinitis allergicRespiratory, thoracic and mediastinal disorders5/1552/154

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fluticasone Furoate/Vilanterol 200/25 µg ODFluticasone Propionate 500 µg Twice Daily (BID)Total
Mean46.9 ± 12.9348.8 ± 13.4147.9 ± 13.19
Gender
Gender(Participants)Fluticasone Furoate/Vilanterol 200/25 µg ODFluticasone Propionate 500 µg Twice Daily (BID)Total
Female9686182
Male5968127
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Fluticasone Furoate/Vilanterol 200/25 µg ODFluticasone Propionate 500 µg Twice Daily (BID)Total
Asian - East Asian Heritage128127255
Asian - South East Asian Heritage272754
08

Study locations

24 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510120, China
  • GSK Investigational Site
    Changsha, Hunan 410011, China
  • GSK Investigational Site
    Shenyang, Liaoning 110001, China
  • GSK Investigational Site
    Shenyang, Liaoning 110015, China
  • GSK Investigational Site
    Beijing, 100020, China
  • GSK Investigational Site
    Beijing, 100029, China
  • GSK Investigational Site
    Beijing, 100191, China
  • GSK Investigational Site
    Chongqing, 400037, China
  • GSK Investigational Site
    Chongqing, 400038, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200032, China
  • GSK Investigational Site
    Shanghai, 200080, China
  • GSK Investigational Site
    Bucheon-si, Gyeonggi-Do, 420-767, Korea, Republic of
  • GSK Investigational Site
    Cheongju, Chungcheongbuk-do, 361-711, Korea, Republic of
  • GSK Investigational Site
    Ilsanseo-gu, Goyang-si, Gyeonggi-do, 411706, Korea, Republic of
  • GSK Investigational Site
    Pusan, 602-739, Korea, Republic of
  • GSK Investigational Site
    Seongnam-si, Gyeonggi-do, 463-707, Korea, Republic of
  • GSK Investigational Site
    Seoul,, 120-752, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 130-709, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 152-703, Korea, Republic of
  • GSK Investigational Site
    Lipa City, 4217, Philippines
  • GSK Investigational Site
    Quezon City, 1100, Philippines
09

References and documents

Publications

  • Lin J, Kang J, Lee SH, Wang C, Zhou X, Crawford J, Jacques L, Stone S. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respir Med. 2015 Jan;109(1):44-53. doi: 10.1016/j.rmed.2014.10.012. Epub 2014 Oct 31. PubMed 25524507 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2011
First posted
Dec 23, 2011
Start
Jan 2012
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Dec 20, 2013
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01498653
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 23, 2011
Start date
Jan 2012
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Dec 20, 2013
Last update
Jan 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GW685698 · Vilanterol

Start the discussion